US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5026687A (en) | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
DE69132332T2 (de) | 1990-04-06 | 2000-11-30 | Genelabs Technologies, Inc. | Hepatitis c-virus-epitope |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
DE4207363A1 (de) | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
EP0662157B1 (en) | 1992-09-10 | 2001-06-20 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis c virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
ATE181557T1 (de) | 1993-02-24 | 1999-07-15 | Jui H Wang | Zusammensetzungen und methoden zur anwendung von reaktiven antiviralen polymeren |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5846964A (en) | 1993-07-19 | 1998-12-08 | Tokyo Tanabe Company Limited | Hepatitis C virus proliferation inhibitor |
DE4415539C2 (de) | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Pflanzen mit virustatischer und antiviraler Wirkung |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
DE4432623A1 (de) | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Verfahren zur Bleichung von wäßrigen Tensidlösungen |
GB9505025D0 (en) | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | C型肝炎の予防・治療剤 |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
EP0914421A2 (en) | 1996-02-29 | 1999-05-12 | Immusol, Inc. | Hepatitis c virus ribozymes |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5830905A (en) | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
US5891874A (en) | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5837257A (en) | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
GB9617177D0 (en) | 1996-08-15 | 1996-09-25 | Kvaerner H & G Offshore Ltd | Downhole valve actuation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
ES2169880T3 (es) | 1996-10-18 | 2002-07-16 | Vertex Pharma | Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c. |
EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
IL119833A (en) | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
DK0946169T3 (da) | 1996-12-20 | 2003-04-22 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af et præparat med vedvarende frigivelse |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
JP3963488B2 (ja) | 1997-06-30 | 2007-08-22 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン | 1−アミノ−アルキルシクロヘキサンnmda受容体拮抗薬 |
DE69827956T2 (de) | 1997-08-11 | 2005-04-14 | Boehringer Ingelheim (Canada) Ltd., Laval | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
EA200700564A1 (ru) | 1998-02-25 | 2007-08-31 | Эмори Юниверсити | 2`-фторнуклеозиды |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6833361B2 (en) | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
GB9821058D0 (en) | 1998-09-28 | 1998-11-18 | Univ Cardiff | Chemical compound |
CN1346360A (zh) | 1999-02-12 | 2002-04-24 | 葛兰素集团有限公司 | 作为抗病毒剂的(1r,顺式)-4-(6-氨基-9h-嘌呤-9-基)-2-环戊烯-1-甲醇的氨基磷酸酯及一二和三磷酸酯 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
EP1225899A2 (en) | 1999-11-04 | 2002-07-31 | Virochem Pharma Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
CA2400274A1 (en) | 2000-02-18 | 2001-08-23 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
US7094770B2 (en) | 2000-04-13 | 2006-08-22 | Pharmasset, Ltd. | 3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
GB0009486D0 (en) | 2000-04-17 | 2000-06-07 | Univ Cardiff | Chemical compounds |
GB0011203D0 (en) | 2000-05-09 | 2000-06-28 | Univ Cardiff | Chemical compounds |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
BR0111196A (pt) | 2000-05-26 | 2004-04-06 | Idenix Cayman Ltd | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus |
MXPA03000626A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
CA2418199A1 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CN1133642C (zh) | 2000-10-09 | 2004-01-07 | 清华大学 | 核苷5’-硫代磷酰氨基酸酯化合物 |
PT2251015E (pt) | 2000-10-18 | 2013-04-15 | Gilead Pharmasset Llc | Nucleosídeos modificados para o tratamento de infeções virais e de proliferação celular anormal |
AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
AU2002236591B2 (en) | 2000-12-12 | 2005-07-14 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2002230764A1 (en) | 2000-12-13 | 2002-06-24 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
US20040266723A1 (en) | 2000-12-15 | 2004-12-30 | Otto Michael J. | Antiviral agents for treatment of Flaviviridae infections |
US7105499B2 (en) | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
AU2002243791B2 (en) | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US8481712B2 (en) | 2001-01-22 | 2013-07-09 | Merck Sharp & Dohme Corp. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
WO2002070533A2 (en) | 2001-03-01 | 2002-09-12 | Pharmasset Ltd. | Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
US20040209831A1 (en) | 2002-02-20 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA) |
GB0112617D0 (en) | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
EP1404694A1 (en) | 2001-06-21 | 2004-04-07 | Glaxo Group Limited | Nucleoside compounds in hcv |
US7022323B2 (en) | 2001-06-26 | 2006-04-04 | Progenics Pharmaceuticals, Inc. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
EP1438054A4 (en) | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUS AND PESTIVIRUS USING MODIFIED NUCLEOSIDE AT 4 'POSITION |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
AU2003209045B2 (en) | 2002-02-13 | 2006-12-14 | Isis Pharmaceuticals, Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
ATE519774T1 (de) | 2002-02-20 | 2011-08-15 | Sirna Therapeutics Inc | Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina) |
US7285658B2 (en) | 2002-02-28 | 2007-10-23 | Biota, Inc. | Nucleotide mimics and their prodrugs |
AU2003301959A1 (en) | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
US6869964B2 (en) | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
DE60336550D1 (de) | 2002-05-20 | 2011-05-12 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
US20040014108A1 (en) | 2002-05-24 | 2004-01-22 | Eldrup Anne B. | Oligonucleotides having modified nucleoside units |
AU2003251524A1 (en) | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Carbocyclic nucleoside analogs as RNA-antivirals |
EP1551421A2 (en) | 2002-06-21 | 2005-07-13 | Merck & Co. Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
JP2006512288A (ja) | 2002-06-27 | 2006-04-13 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体 |
CN103275159A (zh) | 2002-06-28 | 2013-09-04 | 埃迪尼克斯医药公司 | 用于治疗黄病毒感染的修饰的2’和3’-核苷前药 |
JP5087211B2 (ja) | 2002-06-28 | 2012-12-05 | イデニクス(ケイマン)リミテツド | フラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ |
NZ537662A (en) | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
KR20050035194A (ko) | 2002-06-28 | 2005-04-15 | 이데닉스 (케이만) 리미티드 | 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘 |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
AU2003269902A1 (en) | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
WO2004009020A2 (en) | 2002-07-24 | 2004-01-29 | Merck & Co., Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
US20040067877A1 (en) | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
US20040229840A1 (en) | 2002-10-29 | 2004-11-18 | Balkrishen Bhat | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
WO2004046331A2 (en) | 2002-11-15 | 2004-06-03 | Idenix (Cayman) Limited | 2’-branched nucleosides and flaviviridae mutation |
TWI332507B (en) | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
CA2509687C (en) | 2002-12-12 | 2012-08-14 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
AR043006A1 (es) | 2003-02-12 | 2005-07-13 | Merck & Co Inc | Proceso para preparar ribonucleosidos ramificados |
US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
EP1656093A2 (en) | 2003-05-14 | 2006-05-17 | Idenix (Cayman) Limited | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses |
WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
EP2604620B9 (en) | 2003-05-30 | 2024-10-23 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
DE602004003389T2 (de) | 2003-06-19 | 2007-09-13 | F. Hoffmann-La Roche Ag | Verfahren zur herstellung von 4'-azidonukleosidderivaten |
GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
US20050043266A1 (en) | 2003-07-25 | 2005-02-24 | Sumedha Jayasena | Short interfering RNA as an antiviral agent for hepatitis C |
CA2541634A1 (en) | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
SG136123A1 (en) | 2004-03-04 | 2007-10-29 | Leuven K U Res & Dev | Phosponate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production |
WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
RU2007102281A (ru) | 2004-06-23 | 2008-07-27 | Айденикс (Кайман) Лимитед (Ky) | 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae |
CN1972696B (zh) | 2004-06-24 | 2010-08-11 | 默沙东公司 | 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯 |
WO2006000085A1 (en) | 2004-06-28 | 2006-01-05 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
PL216369B1 (pl) | 2004-07-27 | 2014-03-31 | Gilead Sciences | Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV |
CA2577526A1 (en) | 2004-08-23 | 2006-03-02 | Joseph Armstrong Martin | Antiviral 4'-azido-nucleosides |
JP2008511633A (ja) | 2004-08-27 | 2008-04-17 | シェーリング コーポレイション | C型肝炎ウィルスns3セリンプロテアーゼの阻害因子としてのアシルスルホンアミド化合物 |
WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
US20080280842A1 (en) | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
US8399428B2 (en) | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
MX2007010460A (es) | 2005-02-28 | 2007-11-08 | Genelabs Tech Inc | Compuestos de nucleosido triciclico para tratar infecciones virales. |
US8802840B2 (en) | 2005-03-08 | 2014-08-12 | Biota Scientific Management Pty Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
EP1898934A1 (en) | 2005-03-09 | 2008-03-19 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
AR056327A1 (es)* | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
JP4705164B2 (ja) | 2005-05-02 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤 |
WO2007027248A2 (en) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | 3', 5' - cyclic nucleoside analogues for treatment of hcv |
JP2009513564A (ja) | 2005-08-09 | 2009-04-02 | メルク エンド カムパニー インコーポレーテッド | Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体 |
CA2618713A1 (en) | 2005-08-12 | 2007-02-22 | Merck & Co., Inc. | Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives |
JP2009504704A (ja) | 2005-08-15 | 2009-02-05 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ウイルス4′−置換プロヌクレオチドホスホルアミダート |
EA200800932A1 (ru) | 2005-09-26 | 2008-10-30 | Фармассет, Инк. | Модифицированные 4`-нуклеозиды в качестве противовирусных агентов |
CN101511375B (zh) | 2005-12-02 | 2012-09-05 | 耶鲁大学 | L-胞嘧啶核苷类似物在制备用于治疗癌症和其它病症或疾病状态的药物中的应用 |
BRPI0619563A2 (pt) | 2005-12-09 | 2011-10-04 | Pharmasset Inc | nucleosìdeos antivirais |
ES2422290T3 (es) | 2005-12-23 | 2013-09-10 | Idenix Pharmaceuticals Inc | Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados |
AU2007215114A1 (en) | 2006-02-14 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
CN101460488A (zh) | 2006-04-04 | 2009-06-17 | 弗·哈夫曼-拉罗切有限公司 | 用于hcv治疗的3’,5’-二-o-酰化核苷 |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
MY145314A (en) | 2006-10-10 | 2012-01-13 | Medivir Ab | Hcv nucleoside inhibtor |
KR101057239B1 (ko) | 2006-10-10 | 2011-08-16 | 에프. 호프만-라 로슈 아게 | 뉴클레오사이드 리보푸라노실 피리미딘의 제조 |
GB0623493D0 (en) | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
JP2010512365A (ja) | 2006-12-11 | 2010-04-22 | エフ.ホフマン−ラ ロシュ アーゲー | 4’−アジドシチジン誘導体の製造方法 |
US8148349B2 (en) | 2006-12-20 | 2012-04-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US20100056468A1 (en) | 2007-01-08 | 2010-03-04 | University Health Network | Pyrimidine Derivatives As Anticancer Agents |
WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
CN101784557A (zh) | 2007-05-14 | 2010-07-21 | Rfs制药公司 | 用于治疗病毒感染的叠氮基嘌呤核苷 |
US20090048189A1 (en) | 2007-08-15 | 2009-02-19 | Genelabs Technologies, Inc. | Tricyclic-nucleoside compounds for treating viral infections |
GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
US20090318380A1 (en) | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
WO2009146123A2 (en) | 2008-04-03 | 2009-12-03 | Spring Bank | Compositions and methods for treating viral infections |
CN104262345B (zh) | 2008-04-23 | 2017-06-23 | 吉利德科学公司 | 用于抗病毒治疗的1’‑取代的carba‑核苷类似物 |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
CN102177172A (zh) | 2008-07-02 | 2011-09-07 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
GB0815968D0 (en) | 2008-09-03 | 2008-10-08 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010039548A2 (en) | 2008-09-23 | 2010-04-08 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
CN102325783A (zh)* | 2008-12-23 | 2012-01-18 | 法莫赛特股份有限公司 | 嘌呤核苷的合成 |
BRPI0922508A8 (pt) | 2008-12-23 | 2016-01-19 | Pharmasset Inc | Análogos de nucleosídeo |
JP2012514657A (ja) | 2009-01-09 | 2012-06-28 | ユニバーシテイ・カレツジ・オブ・カーデイフ・コンサルタンツ・リミテツド | ウィルス感染を治療するためのグアノシンヌクレオシド化合物のホスホルアミダート誘導体 |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
BRPI1005401A2 (pt) | 2009-02-06 | 2019-04-02 | Rfs Pharma, Llc | pro-farmácos de purina nucleosídeo monofosfato para o tratamento de câncer e infecções virais |
UA112140C2 (uk) | 2009-02-10 | 2016-07-25 | Гіліад Сайєнсіз, Інк. | Нуклеозидні похідіні (варіанти), фармацевтична композиція на їх основі, спосіб лікування вірусної інфекції та застосування сполуки для виробництва лікарського засобу |
EP2408306A4 (en) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
WO2010108135A1 (en) | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
NZ597535A (en) | 2009-07-06 | 2013-12-20 | Trilink Biotechnologies | Chemically modified ligase cofactors, donors and acceptors |
US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US7973013B2 (en) | 2009-09-21 | 2011-07-05 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
US20100077085A1 (en) | 2009-09-23 | 2010-03-25 | Joseph Chyam Cohen | Systems and method for configuring display resolution in a terminal server environment |
US8552021B2 (en) | 2009-09-29 | 2013-10-08 | Janssen Products, L.P. | Phosphoramidate derivatives of nucleosides |
AP2012006310A0 (en) | 2009-11-16 | 2012-06-30 | Univ Georgia | 2'fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections. |
US8816074B2 (en) | 2009-11-16 | 2014-08-26 | University of Georgia Foundation, Inc. | 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections |
BR112012015951A2 (pt) | 2010-01-28 | 2018-10-16 | Hoffmann La Roche | 4 azido-nucleosídeos como compostos anti-hcv |
CA2791630A1 (en) | 2010-03-04 | 2011-09-09 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of hcv replication |
ES2900773T3 (es) | 2010-03-31 | 2022-03-18 | Gilead Pharmasset Llc | Comprimido que comprende (S)-isopropilo 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2h)-il)-4-fluoro3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato cristalino |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
CA2795054A1 (en)* | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
US20110306541A1 (en) | 2010-06-10 | 2011-12-15 | Gilead Sciences, Inc. | Methods for treating hcv |
JP5937073B2 (ja) | 2010-07-19 | 2016-06-22 | ギリード・サイエンシズ・インコーポレーテッド | ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法 |
TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
EA025341B1 (ru) | 2010-09-22 | 2016-12-30 | Алиос Биофарма, Инк. | Замещенные аналоги нуклеотидов |
WO2012040124A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
WO2012040126A1 (en)* | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
WO2012048013A2 (en) | 2010-10-06 | 2012-04-12 | Inhibitex, Inc. | Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections |
ES2605433T3 (es) | 2010-11-10 | 2017-03-14 | Janssen Products, L.P. | Fosforamidatos de espironucleósido oxetánico uracílico |
US9012428B2 (en) | 2010-11-10 | 2015-04-21 | Janssen Products, Lp | Uracyl spirooxetane nucleoside phosphoramidates |
TW201242974A (en) | 2010-11-30 | 2012-11-01 | Gilead Pharmasset Llc | Compounds |
US20130273005A1 (en) | 2010-12-20 | 2013-10-17 | Gilead Sciences, Inc. | Methods for treating hcv |
EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
EP2658857B1 (en) | 2010-12-29 | 2016-11-02 | Inhibitex, Inc. | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections |
WO2012094248A1 (en) | 2011-01-03 | 2012-07-12 | Nanjing Molecular Research, Inc. | O-(substituted benzyl) phosphoramidate compounds and therapeutic use |
US9156874B2 (en) | 2011-01-03 | 2015-10-13 | Nanjing Molecular Research, Inc. | Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs |
US9085599B2 (en) | 2011-03-16 | 2015-07-21 | Enanta Pharmaceuticals, Inc. | 2′allene-substituted nucleoside derivatives |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
KR20140019832A (ko) | 2011-04-13 | 2014-02-17 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료를 위한 1''-치환 피리미딘 ν-뉴클레오사이드 유사체 |
EP2697242B1 (en) | 2011-04-13 | 2018-10-03 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
CN103582420B (zh)* | 2011-04-13 | 2016-10-19 | 默沙东公司 | 2’-取代的核苷衍生物和使用其治疗病毒病的方法 |
CA2832449A1 (en) | 2011-04-13 | 2012-10-18 | Vinay GIRIJAVALLABHAN | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
WO2012158811A2 (en) | 2011-05-19 | 2012-11-22 | Rfs Pharma, Llc | Purine monophosphate prodrugs for treatment of viral infections |
WO2013009737A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
WO2013009735A1 (en) | 2011-07-13 | 2013-01-17 | Merck Sharp & Dohme Corp. | 5'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
CN103987712B (zh) | 2011-07-19 | 2016-05-04 | 河南美泰宝生物制药有限公司 | 2’,3’-二脱氧-2’-α-氟-2’-β-C-甲基核苷和其前药 |
AR088441A1 (es) | 2011-09-12 | 2014-06-11 | Idenix Pharmaceuticals Inc | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales |
CA2847892A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013044030A1 (en) | 2011-09-23 | 2013-03-28 | Enanta Pharmaceuticals, Inc. | 2'-chloroacetylenyl substituted nucleoside derivatives |
EP2768838A1 (en) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013084165A1 (en) | 2011-12-05 | 2013-06-13 | Medivir Ab | Hcv polymerase inhibitors |
UA111761C2 (uk) | 2011-12-20 | 2016-06-10 | Рібосаєнс Ллс | 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c |
CN104011060A (zh) | 2011-12-20 | 2014-08-27 | 弗·哈夫曼-拉罗切有限公司 | 作为hcv rna复制抑制剂的4‘-叠氮基,3’-氟取代的核苷衍生物 |
US20140356325A1 (en) | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
CA2873315A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharamaceuticals, Inc. | D-amino acid compounds for liver disease |
US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
US9296778B2 (en) | 2012-05-22 | 2016-03-29 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphate prodrugs for HCV infection |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
TR201809048T4 (tr) | 2012-10-08 | 2018-07-23 | Centre Nat Rech Scient | Hcv enfeksiyonu için 2'-kloro nükleosit analogları. |
AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
US9242988B2 (en) | 2012-10-17 | 2016-01-26 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP2909223B1 (en) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Dinucleotide compounds for hcv infection |
WO2014066239A1 (en) | 2012-10-22 | 2014-05-01 | Idenix Pharmaceuticals, Inc. | 2',4'-bridged nucleosides for hcv infection |
WO2014078427A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-alanine ester of rp-nucleoside analog |
US20140140952A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Sp-Nucleoside Analog |
US20140205566A1 (en) | 2012-11-30 | 2014-07-24 | Novartis Ag | Cyclic nucleuoside derivatives and uses thereof |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
WO2014124430A1 (en) | 2013-02-11 | 2014-08-14 | Emory University | Nucleotide and nucleoside therapeutic compositions and uses related thereto |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
WO2014137930A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Thiophosphate nucleosides for the treatment of hcv |
EP2970357B1 (en) | 2013-03-13 | 2025-01-01 | Idenix Pharmaceuticals LLC | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
CN103848876B (zh) | 2013-03-25 | 2016-05-11 | 安徽贝克联合制药有限公司 | 一种核苷磷酰胺前药及其制备方法和其应用 |
EP2981542B1 (en) | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
EP3010512B1 (en) | 2013-06-18 | 2017-12-27 | Merck Sharp & Dohme Corp. | Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
WO2015061683A1 (en) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv |
US20160271162A1 (en) | 2013-11-01 | 2016-09-22 | Idenix Pharmacueticals, Llc | D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv |
US20160280729A1 (en) | 2013-11-20 | 2016-09-29 | Idenix Pharmaceuticals Llc | Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv |
EP3074411A2 (en) | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | Nucleotides for the treatment of liver cancer |
WO2015081297A1 (en) | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
CN103848877B (zh) | 2013-12-16 | 2016-08-24 | 安徽贝克联合制药有限公司 | 核苷环磷酸酯化合物及其制备方法和其应用 |
WO2015095305A1 (en) | 2013-12-17 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds |
WO2015095419A1 (en) | 2013-12-18 | 2015-06-25 | Idenix Pharmaceuticals, Inc. | 4'-or nucleosides for the treatment of hcv |
US20170066795A1 (en) | 2014-03-05 | 2017-03-09 | Idenix Pharmaceuticals Llc | Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv |
US10202411B2 (en) | 2014-04-16 | 2019-02-12 | Idenix Pharmaceuticals Llc | 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV |